Proteus mirabilis forms dense crystalline biofilms on catheter surfaces that occlude 28 urine flow leading to serious clinical complications in long-term catheterised patients, 29 but there are presently no truly effective approaches to control catheter blockage by 30 this organism. This study evaluated the potential for bacteriophage therapy to control 31 P. mirabilis infection and prevent catheter blockage. Representative in vitro models of 32 the catheterised urinary tract, simulating a complete closed drainage system as used 33 in the catheterised urinary tract and often responds poorly to conventional antibiotic 71 therapy. It can persist despite multiple catheter changes or periods without 72 catheterisation, and causes chronic infection and blockage in many patients (8, 9, 73 11). There are presently no truly effective strategies for the control of P. mirabilis 74 CAUTI and associated blockage, and the development of new approaches is urgently 75 required. The aim of this study was to determine if bacteriophage (phage) therapy 76 on August 3, 2016 by QUEEN'S UNIVERSITY BELFAST http://aac.asm.org/ Downloaded from Preparation of high titre phage stocks. Phage were propagated on P. mirabilis 126 RS1 host and high titre stocks obtained. Briefly, 100 μl of phage suspension and 100 127 μl of host growing culture were mixed, combined with 3 ml of molten S-LBDA, swirled 128 on August 3, 2016 by QUEEN'S UNIVERSITY BELFAST http://aac.asm.org/ Downloaded from and the encrustation of urethral catheters. Urol Res 21:407-411. 409 on August 3, 2016 by QUEEN'S UNIVERSITY BELFAST http://aac.asm.org/ Downloaded from bladder model media at end of experiments D) Enumeration of viable cells in residual 502 urine in bladder models at the end of experimentsno significant differences. All 503 data: Data represent the mean of three replicate experiments, and error bars show 504 on August 3, 2016 by QUEEN'S UNIVERSITY BELFAST http://aac.asm.org/ Downloaded from
in clinical practice, were employed to evaluate the performance of phage therapy in 34 preventing blockage. Models mimicking either an established infection, or early 35 colonisation of the catheterised urinary tract, were treated with a single dose of a 3 36 phage cocktail, and the impact on time taken for catheters to block, as well as levels 37 of crystalline biofilm formation, were measured. In models of established infection 38 phage treatment significantly increased time taken for catheters to block (~3-fold) 39 compared to untreated controls. However, in models simulating early stage infection 40 phage treatment eradicated P. mirabilis and prevented blockage entirely. Analysis of 41 catheters from models of established infection, 10 hours after phage application, 42 demonstrated that phage significantly reduced crystalline biofilm formation, but did 43 not significantly reduce the level of planktonic cells in the residual "bladder" urine. 44
Taken together, these results show that bacteriophage constitute a promising 45 strategy for the prevention of catheter blockage, but that methods to deliver phage in 46 sufficient numbers and within a key therapeutic window (early infection) will also be 47 important to the successful application of phage to this problem. A frequent complication associated with long-term urethral catheterisation is 52 encrustation and blockage of catheters due to infection with Proteus mirabilis, which 53 can be isolated from around 45% of catheter associated urinary tract infections 54 (CAUTI) (1, 2) . Blockage stems from the ability of P. mirabilis to form dense biofilms 55 on catheter surfaces, and the production of a potent urease enzyme which generates 56 ammonia through hydrolysis of urea (1, 3, 4) . Ammonia production elevates urinary 57 pH causing the precipitation of calcium and magnesium phosphates, and the 58 subsequent formation of crystals which become trapped within developing biofilms (1, 59 5) . Once embedded in the biofilm, crystal growth is stabilised and enhanced by the 60 biofilm matrix (6, 7) . As this process continues the biofilm gradually becomes 61 mineralised, leading to development of extensive crystalline biofilm structures which 62 ultimately block catheters (1, 5) . If unnoticed, blockage can lead to reflux of infected 63 urine to the upper urinary tract, and the onset of serious clinical complications 64 including pyelonephritis, septicaemia, and shock (1, 8) . 65
66
Although catheters containing antimicrobial coatings are currently available, their 67 efficacy in preventing infection during even short-term use remains questionable, and 68 all available catheter types remain susceptible to P. mirabilis encrustation and 69 blockage (9, 10). P. mirabilis is also extremely difficult to eliminate once established 70 may constitute a viable approach to the prevention of catheter encrustation and 77 blockage. 78
79

MATERIALS AND METHODS 80
Bacterial strains, media, routine culture. Clinical isolates of P. mirabilis 81 (designated RS1 and RS3) used in this study were obtained from the Royal Sussex 82
County Hospital, and all were derived from urinary tract infections. All chemicals, 83 reagents and growth media were obtained either from Fisher Scientific UK, Oxoid 84 UK, or Sigma UK unless otherwise stated. Bacteria were routinely cultured in 85
Lysogeny-Broth Derivative Broth (LBDB) medium (5 g/l Yeast Extract, 10 g/l 86
Vegetable peptone Nº1, 10 g/l Sodium Chloride) at 37°C with shaking, or on LBDB 87
solidified by the addition of 15 g/l Technical agar (LBDA). Soft agar overlays, used for 88 phage enrichments, purification and enumeration, were derived from LBDA (S-LBDA) 89 and contained 5 g/l Yeast extract, 10 g/l Vegetable peptone Nº1, and 5.75 g/l 90
Technical agar, and was kept molten at 45ºC for use in agar overlays. The artificial 91 urine (AU) medium previously described by Stickler et al. (12) , was initially prepared 92 as a 5X concentrated stock solution containing sodium disulfate (11.5 g/l), 93 magnesium chloride (hexahydrate) (3.25 g/l), sodium chloride (23 g/l), trisodium 94 citrate (3.25 g/l), sodium oxalate (0.1 g/l), potassium dihydrogen orthophosphate (14 95 g/l), potassium chloride (8 g/l), ammonium chloride (5 g/l), calcium chloride dihydrate 96 (3.25 g/l), urea (125 g/l), gelatin (25 g/l), and tryptone soya broth (5 g/l wastewater treatment plants in the UK (Anglian water, Luton area). For initial 105 enrichments of P. mirabilis phage 387.5 ml of LBDB was mixed with 100 ml of 106 sewage, and inoculated with 2.5 ml of host growing cultures of P. mirabilis. 107
Enrichments were incubated statically overnight at 37ºC and the following day 10 ml 108 aliquots were recovered, centrifuged (3000 X g for 30 min), and supernatants filtered 109 into fresh sterile tubes using 0.22 µm pore syringe filters (Sartorius, United Kingdom). to repeat agar overlays with host strains of P. mirabilis used in initial isolation. To 120 ensure clonality of phage types, this process was repeated a further 5 times until 121 bacterial lawns showed homogeneity of plaque morphology. Finally, an individual 122 plaque was picked off and resuspended in SM buffer for use in subsequent 123 experiments. These final clonal phage suspensions were stored at 4ºC until required. 124 gently and poured onto agar plates. After a static overnight incubation at 37°C, plates 129 displaying confluent lysis were selected and 3 ml of SM buffer supplemented with 2% 130
(v/v) chloroform (to lyse remaining bacterial cells and maximize yield) were added 131 before incubation at 37°C for 4 h. High-titre phage solution was removed from the 132 plates, centrifuged (8,000 X g for 10 min) to remove cell debris, and then filter-133 sterilised (pore size, 0.22 μm) and stored at 4°C. experiments, and are inserted into the "bladder" via an outlet in the base of the glass 141 chamber, before retention balloons are inflated with 10 ml sterile water. Catheters 142 were subsequently attached to a drainage bag to form a sterile closed drainage 143 system, and AU medium supplied at a constant flow rate of 0.75 ml /min. P. mirabilis 144 RS1 cell suspensions were inoculated directly into the residual bladder urine at either 145 10 10 cfu or 10 3 cfu representing late sage or early stage infection respectively, and 146 flow suspended for 1h to permit cells to establish within the system. 45 min after 147 bacterial inoculation, test models were treated with a single dose of 3 x 10 10 pfu of a 148 3 phage cocktail (1:1:1, 10 10 pfu of each phage) in a volume of 1 ml, and flow 149 restored 15 min later. The numbers of viable cells present in the residual bladder 150 medium were enumerated at the start and end of experiments, and pH was also 151 measured at the start and end of experiments by sampling the medium in the Quantification of crystalline biofilm formation on catheter sections. To measure 155 the levels of crystalline biofilm formation and catheter encrustation in control and 156 phage treated models, the amount of calcium present on catheter sections removed 157 from bladder models run for a set time (10 h) was quantified by flame photometry, 158 described previously (13). Briefly, 1 cm catheter sections were submerged in 2 ml of 159 an ammonium oxalate and oxalic acid solution (95% and 5% vol/vol respectively from 160 0.1 M stock solutions), subject to vigorous mixing for 3 min, then incubated at room 161 temperature for 30 min. Catheter sections were then removed, the remaining mixture 162 centrifuged (3000 X g for 10 min) and the supernatant discarded. Pellets were 163 resuspended in 5 ml perchloric acid (0.05 M), samples mixed thoroughly, centrifuged 164
(3000 X g for 2 min), and supernatants recovered. Levels of calcium dissolved in 165 supernatants were determined using a flame photometer (Corning, Flame 166
Photometer 410), calibrated using calcium standards at 100, 75, 50 and 25 ppm. draining freely for > 8 days until media reserves were exhausted (Fig. 3) . In contrast, 211 catheters in corresponding control models developed substantial encrustation, and 212 became blocked after ~2 days (Fig. 3) . sections quantified. This demonstrated that phage treatment significantly reduced 218 levels of encrustation (Fig. 4A) . These data were supported by direct SEM 219 visualisation of catheter sections, which showed sections from models treated with 220 phage to be devoid of visible crystalline deposits. This was in stark contrast to 221 catheter sections from untreated models, which exhibited prominent encrustations 222 ( Fig. 4B) . While these observations corresponded with a significant reduction in pH in 223 treated models, the number of viable planktonic cells in residual urine from test or 224 control models was not found to be significantly different (Fig. 4C,D) . been reported when catheter sections were pretreated with phage suspensions (14, 234 15, 16). More recently, Lehman and Donlan (17) have described phage pretreatment 235 for control of mixed species biofilm formation (P. aeruginosa & P. mirabilis), and also 236 evaluated encrustation of catheter sections. However, these previous studies were 237 able to show a reduction, rather than complete prevention, of biofilm formation by 238 uropathogens tested, and where P. mirabilis was used phage did not fully prevent 239 encrustation (14, 16, 17) . 240
241
In contrast our data highlight the potential for a more dramatic impact of phage 242 therapy in preventing blockage and resolution of P. mirabilis infection. Although 243 specific attributes of the phage used in this study may be important to the outcome of 244 bladder model experiments reported here, the differences in phage performance 245 noted between this and other studies most likely relates to the high titres of phage 246 achieved in bladder models, and delivery directly to residual bladder urine. In 247 contrast, previous studies targeting P. mirabilis or other uropathogens have focused 248 on the pretreatment of catheter sections with phage suspensions prior to use in 249 models of biofilm formation (14, 15, 16, 17) . As a result, the final titres of phage 250 tested in these systems (and resulting MOIs established) was unclear, but likely to be 251 substantially lower than those obtained in our models. 252
253
In addition, previous evaluations of phage therapy for CAUTI have mainly been 254 designed to evaluate the ability of phage to reduce biofilm formation in general, 255 rather than prevent catheter blockage specifically. In this context, the focus of our 256 study on blockage as a specific therapeutic end point, and the evaluation of phage 257 using a full closed drainage system in the bladder model system is also a key from the manufacturing process] that are particularly supportive of bacterial 273 colonisation, and are continually exposed to the sump of infected residual urine that 274 accumulates in the bladder (1, 12, 13) . Therefore, the bladder model system provides Previous evaluations of P. mirabilis phage have indicated that these remain active 296 even under conditions of high pH (17). Our own evaluation of specific phage used 297 here confirms these remain capable of infection after exposure to high pH (data not 298 shown), but the possibility that alterations to cell surface properties protects against 299 infection with these specific phage at high pH cannot be excluded. 300
301
Alternatively, the failure of phage to prevent blockage in late stage infection may be 302 explained by the development of resistance to the phage used, and this has been 303 observed in other studies of phage therapy for CAUTI over a similar time frame (16). 304
Although the use of a three phage cocktail should guard against resistance, the 305 phage used here have similar host range profiles, are all members of the Podoviridae 306 family, and are yet to be characterised genetically. It is therefore possible that they 307 constitute closely related phage types with comparable mechanisms of attachment 308 and infection. This could allow the same mutation(s) in host bacteria to afford 309 resistance to all three. In this context it is notable also that many key surface 310 on August 3, 2016 by QUEEN'S UNIVERSITY BELFAST http://aac.asm.org/ Downloaded from structures of P. mirabilis that may be receptors for phage attachment are subject to 311 phase variable gene expression (18), and it is therefore not unlikely that a small 312 proportion of a given P. mirabilis population may be naturally immune to particular 313 phage types, and selected for during phage treatment. In summary, the current study supports the potential efficacy of phage therapy in 366 control of CAUTI, and in particular blockage caused by P. mirabilis. Although there is 367 a clear need for further fundamental research into phage:host interactions and the 368 ability of phage to control CAUTI to progress this approach, our work also suggests a 369 major factor in the successful use of phage therapy in this setting will be the parallel 370 development of strategies to deliver sufficient numbers of phage within the most 371 effective therapeutic window (e.g. early stage infection for P. mirabilis CAUTI). 
